IMR Press / FBL / Volume 16 / Issue 5 / DOI: 10.2741/3826

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article
Emerging metabolic targets in cancer therapy
Show Less
1 Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA
2 Ochsner Health System, Ochsner Cancer Institute, Department of Surgery, New Orleans, LA 70121, USA
3 Institute for Cancer Research, The Norwegian Radium Hospital, 0310 Oslo, Norway
4 Department of Cell Biology and Neuroscience, College of Medicine, University of South Alabama, Mobile, AL 36608, USA
Front. Biosci. (Landmark Ed) 2011, 16(5), 1844–1860; https://doi.org/10.2741/3826
Published: 1 January 2011
Abstract

Cancer cells are different from normal cells in their metabolic properties. Normal cells mostly rely on mitochondrial oxidative phosphorylation to produce energy. In contrast, cancer cells depend mostly on glycolysis, the aerobic breakdown of glucose into ATP. This altered energy dependency is known as the "Warburg effect" and is a hallmark of cancer cells. In recent years, investigating the metabolic changes within cancer cells has been a rapidly growing area. Emerging evidence shows that oncogenes that drive the cancer-promoting signals also drive the altered metabolism. Although the exact mechanisms underlying the Warburg effect are unclear, the existing evidence suggests that increased glycolysis plays an important role in support malignant behavior of cancer cells. A thorough understanding of the unique metabolism of cancer cells will help to design of more effective drugs targeting metabolic pathways, which will greatly impact the capacity to effectively treat cancer patients. Here we provide an overview of the current understanding of the Warburg effect upon tumor cell growth and survival, and discussion on the potential metabolic targets for cancer therapy.

Share
Back to top